Beta Lifescience articles

What is CD73?
CD73, also known as ecto-5′-nucleotidase, is a groundbreaking immunoinhibitory protein that assumes a pivotal role in tumor growth and metastasis. Its primary function revolves around converting extracellular ATP into immunosuppressive adenosine, working in tandem with CD39 within normal tissues to curtail excessive immune r

What is CD19
Understanding CD19: Definition and Role in the Immune System
CD19, also known as Cluster of Differentiation 19, is a cell surface protein belonging to the immunoglobulin superfamily. It serves as a crucial marker for B cells, playing a pivotal role in the human immune system. While predominantly found on the surface of B cells, CD19 is rarely expressed on other immune cells. Its significance lies in its involvement in B cell development

About Tumor Suppressor Genes
A tumor suppressor gene, also known as anti-onco gene, is an essential component of the body's defense against cancer. It usually facilitates apoptosis. With its absence, the human body will be functioning without its “brake” of cell proliferation. Cells are potent to go under abnormal growth processes and finally lead to tumor/cancer.

Here are some key features and functions of tumor suppressor genes:

Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing favorable therapeutic efficacy and safety for patients with high-risk or very high-risk prostate cancer. B7-H3 is expressed in limited amou

Autoimmune disease target - IL-17 Family
IL-17 plays an important role in promoting autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis (AS). Currently, five large-molecule biopharmaceuticals targeting IL-17/IL-17R are available worldwide, including four IL-17 monoclonal antibodies and one IL-17RA monoclonal antibody, namely Secukinumab(Novartis), Ixekizumab(Eli Lilly), Netakimab(Biocad), Brodalumab(Kyowa Hakko Kirin), and Bimekizumab(U